Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Novartis
Harvard Business School
Queensland Health
Medtronic
UBS
US Department of Justice
Mallinckrodt
McKinsey

Generated: October 19, 2017

Patent: ► Subscribe

Summary for Patent: ► Subscribe

Title:Optimized drug-eluting stent assembly methods
Abstract: Methods of preparing and using a stent assembly that includes a stent jacket formed from an expansible mesh structure having apertures and that includes a fiber having a diameter of about 7 micrometers and about 40 micrometers, and an expansible stent operatively associated with the stent jacket. The method further comprises administering to the subject an active pharmaceutical ingredient (API) eluted from the stent assembly.
Inventor(s): Bar; Eli (Moshav, IL), Holzer; Asher (Raanana, IL), Paz; Ofir (Rishon Lezion, IL)
Assignee: InspireMD, Ltd. (Tel Aviv, IL)
Application Number:14/851,882
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Centocor Inc
REOPRO
abciximab
INJECTABLE; INJECTION1035750011994-12-22► Subscribe InspireMD, Ltd. (Tel Aviv, IL) Bar; Eli (Moshav, IL), Holzer; Asher (Raanana, IL), Paz; Ofir (Rishon Lezion, IL) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Argus Health
Covington
Cipla
Daiichi Sankyo
Baxter
Citi
AstraZeneca
Harvard Business School
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot